BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 27546731)

  • 1. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
    Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
    J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
    Yi X; Han Z; Zhou Q; Cheng W; Lin J; Wang C
    Clin Appl Thromb Hemost; 2018 Jan; 24(1):55-62. PubMed ID: 27637911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
    Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
    J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack.
    Lu M
    Pak J Pharm Sci; 2017 Jan; 30(1):217-221. PubMed ID: 28603135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
    Rosafio F; Lelli N; Mimmi S; Vandelli L; Bigliardi G; Dell'Acqua ML; Picchetto L; Pentore R; Ferraro D; Trenti T; Nichelli P; Zini A
    J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):1864-1873. PubMed ID: 28576652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
    Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
    CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
    Dunn SP; Steinhubl SR; Bauer D; Charnigo RJ; Berger PB; Topol EJ
    J Am Heart Assoc; 2013 Jan; 2(1):e004564. PubMed ID: 23525436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
    O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
    Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
    Tran M; Tafreshi J; Pai RG
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
    Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
    Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population.
    Yi X; Lin J; Zhou Q; Wu L; Cheng W; Wang C
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1222-1228. PubMed ID: 26935114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
    Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
    Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
    Wang Y; Cai H; Zhou G; Zhang Z; Liu X
    J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.